Bioactive Heterocycles II pp 73-97

Part of the Topics in Heterocyclic Chemistry book series (TOPICS, volume 8)

Synthesis of Thalidomide


Despite the most notorious medical disaster caused by thalidomide in medical history, huge numbers of papers have been published about this drug since its formulation in 1956. While most of the early studies specifically concerned teratogenicity, recently there has been a resurgence of interest in thalidomide because of its potential for treating a number of otherwise intractable diseases, such as leprosy, human immunodeficiency virus replication in acquired immune deficiency syndrome, and cancer. Although the pharmacological aspects of the drug have been frequently reviewed, reviews focusing on thalidomide synthesis are rare. Here, the synthesis of thalidomide is reviewed in chronological order from the first report. We first aim to give an overview of the most conventional aspects of thalidomide. Subsequently, we will focus on the synthesis of racemic thalidomide, which is now commercially available. Finally, we will describe the asymmetric synthesis of thalidomide. To our knowledge, all the papers and patents concerning thalidomide synthesis have been introduced. Because of the number of papers and patents, we will not mention the preparation of thalidomide derivatives.

Asymmetric synthesis Drug synthesis Teratogenicity Thalidomide  


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  1. 1.Graduate School of EngineeringNagoya Institute of TechnologyNagoyaJapan

Personalised recommendations